Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures - Quiz - MDSpire

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • By

  • Mohammed Nabil Quraishi

  • Jonathan Cheesbrough

  • Peter Rimmer

  • Benjamin H Mullish

  • Naveen Sharma

  • Elena Efstathiou

  • Animesh Acharjee

  • Georgios Gkoutus

  • Arzoo Patel

  • Julian R Marchesi

  • Stephane Camuzeaux

  • Katie Chappell

  • Maria A Valdivia-Garcia

  • James Ferguson

  • Matthew J Brookes

  • Martine Walmsley

  • Amanda E Rossiter

  • Willem van Schaik

  • Ross S McInnes

  • Rachel Cooney

  • Michael Trauner

  • Andrew D Beggs

  • Tariq H Iqbal

  • Palak J Trivedi

  • December 14, 2024

  • 0 min

Share

Original Source(s)

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • by Mohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, Benjamin H Mullish, Naveen Sharma, Elena Efstathiou, Animesh Acharjee, Georgios Gkoutus, Arzoo Patel, Julian R Marchesi, Stephane Camuzeaux, Katie Chappell, Maria A Valdivia-Garcia, James Ferguson, Matthew J Brookes, Martine Walmsley, Amanda E Rossiter, Willem van Schaik, Ross S McInnes, Rachel Cooney, Michael Trauner, Andrew D Beggs, Tariq H Iqbal, Palak J Trivedi

  • December 14, 2024

Related Content

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
Renal Conditions Associated with Inflammatory Bowel Disease: Exploring Clinical Links, Shared Mechanisms, and Management Approaches

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment